Nauck MA - Search Results

1

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.

Nauck MA. Nauck MA. Drug Des Devel Ther. 2014 Sep 11;8:1335-80. doi: 10.2147/DDDT.S50773. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25246775 Free PMC article. Review.

2

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Willms B, et al. Among authors: nauck ma. J Clin Endocrinol Metab. 1996 Jan;81(1):327-32. doi: 10.1210/jcem.81.1.8550773. J Clin Endocrinol Metab. 1996. PMID: 8550773 Clinical Trial.

3

Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.

Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA. Willms B, et al. Among authors: nauck ma. Exp Clin Endocrinol Diabetes. 1998;106(2):103-7. doi: 10.1055/s-0029-1211959. Exp Clin Endocrinol Diabetes. 1998. PMID: 9628239 Clinical Trial.

4

[Antidiabetic combination therapy].

Nauck M. Nauck M. Internist (Berl). 2001 Apr;42 Suppl 1:S20-7. doi: 10.1007/s001080170003. Internist (Berl). 2001. PMID: 11370609 Review. German. No abstract available.

5

Incretins and their analogues as new antidiabetic drugs.

Nauck MA, Meier JJ, Creutzfeldt W. Nauck MA, et al. Drug News Perspect. 2003 Sep;16(7):413-22. doi: 10.1358/dnp.2003.16.7.829353. Drug News Perspect. 2003. PMID: 14668937 Review.

6

Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?

Meier JJ, Gallwitz B, Schmidt WE, Mügge A, Nauck MA. Meier JJ, et al. Among authors: nauck ma. Heart. 2004 Jan;90(1):9-12. doi: 10.1136/heart.90.1.9. Heart. 2004. PMID: 14676228 Free PMC article. Review.

7

A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome.

Nauck MA, Meier JJ, Wolfersdorff AV, Tillil H, Creutzfeldt W, Köbberling J. Nauck MA, et al. Acta Diabetol. 2003 Dec;40(4):163-72. doi: 10.1007/s00592-003-0106-y. Acta Diabetol. 2003. PMID: 14740275

8

Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.

Nauck MA, Baller B, Meier JJ. Nauck MA, et al. Diabetes. 2004 Dec;53 Suppl 3:S190-6. doi: 10.2337/diabetes.53.suppl_3.s190. Diabetes. 2004. PMID: 15561910 Review.

9

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.

Nauck MA. Nauck MA. Horm Metab Res. 2004 Nov-Dec;36(11-12):852-8. doi: 10.1055/s-2004-826175. Horm Metab Res. 2004. PMID: 15655719 Review.

10

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.

Nauck MA, El-Ouaghlidi A. Nauck MA, et al. Diabetologia. 2005 Apr;48(4):608-11. doi: 10.1007/s00125-005-1704-8. Epub 2005 Mar 11. Diabetologia. 2005. PMID: 15761719 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results